Compare ADMA Biologics Inc (ADMA) vs Main Street Capital Corporation (MAIN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Main Street Capital Corporation — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Main Street Capital Corporation trades at $51.08 (market cap $4.87B). The key difference: Main Street Capital Corporation is far larger — about 2.3× ADMA Biologics Inc's market cap, and Main Street Capital Corporation pays a 8.36% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | MAIN | |
|---|---|---|
Market Cap | $2.13B | $4.87B |
Sector | Health | Financials |
52-Week High | $20.38 | $67.54 |
52-Week Low | $7.60 | $49.63 |
Enterprise Value | $2.20B | — |
Dividend Yield | — | 8.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Main Street Capital (MAIN) trades at $52.41, up 0.87% on the day, with a bullish technical signal and strong support near $52. The company reported a net income margin of 81.08% for 2025, though revenue declined slightly to $592 million. Recent corporate actions include a credit facility amendment extending maturity to 2031 and consistent dividend payments, highlighting its income-focused appeal.
Outlook remains mixed; the stock offers a high yield and stable dividends, but earnings misses and a high RSI suggest near-term caution. Analyst consensus is a Hold with a $57.75 price target, indicating modest upside potential amid execution risks and economic sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →
